This entry was posted on July 31, 2009 at 9:35 pm and is filed under Aurora.
You can follow any responses to this entry through the RSS 2.0 feed.
You can skip to the end and leave a response. Pinging is currently not allowed.
“…Clinical benefit has been demonstrated with reductions in tumor volume,
reductions in tumor markers, and improvement in cancer-related symptoms
in melanoma, renal cell, ovarian, and colorectal cancer patients….”
ENMD-2076 must be doing good in the Multiple Myeloma trial because one year into the trial the US National Institute for Health thru the National Cancer Institute has agreed to fund a grant to study for ENMD-2076 as a treatment for Multiple Myeloma.
Sherif Shafik Farag NIH-NCI New Multiple kinase target inhibition with EMND-2076 in multiple myeloma 2/1/10 1/31/11 319,550